Hemophilia a with Inhibitors
Conditions
Brief summary
This pilot study will investigate the use of thromboelastograph (TEG) to determine the primary bypassing agent for the management of bleeding in children and adults severe hemophilia A patients with inhibitors. The study will evaluate the TEG profile for each of the available bypassing agents (FEIBA and rFVIIa) in each participating patient, which will then determine which agent provides the most robust clot formation as measured by the TEG. This study will consist of screening visit and 2-4 pharmacokinetic studies to determine the best bypassing agent based on the TEG results. Patients will then be assigned that bypassing agent and dose for the treatment of their bleeding episodes (Prophylaxis or On-demand). Each patient will be then followed for a period of 6 months to monitor short-term safety of those patients whose bypassing agent was modified.
Detailed description
Currently, there are no laboratory assays that can assess the pharmaceutical activity of the available agents known collectively as bypassing agents, which negatively impacts the treating physician's ability to manage these patients, leaving decisions on the dosing regimen to trial and error. Both agents, FEIBA and recombinant activated factor VII (rFVIIa), are approved for the treatment of bleeding in inhibitor patients with recommended dosing regimens that are based on clinical trials. However, a significant amount of experimenting with other dosing regimens is used by physicians and patients. The goal of this project is to demonstrate that TEG is an excellent biomarker for predicting, managing and individualizing the treatment with FEIBA and rFVIIa of this rare and difficult to treat patient population.
Interventions
OTHERThromboelastography-Guided Treatment Regimen
The thromboelastograph (TEG) will be used to determine the best bypassing agent for the management of subjects with severe hemophilia A with inhibitors. Patients will be assigned that bypassing agent and dose for the treatment of their bleeding episodes and subsequently will be followed for a period of 6 months to determine their annual bleeding rate.
Sponsors
Children's Hospital Los Angeles
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
4 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
1. Males, 4-60 years old, inclusive on Prophylaxis or On-Demand treatment 2. Diagnosis of Hemophilia with active titer inhibitors (\> 0.6 BU) 3. Willing to alter their treatment regimen per study protocol
Exclusion criteria
1. Bleeding disorder(s) other than hemophilia A with inhibitors 2. Thrombocytopenia (platelet count \<100,000K/µL) 3. Any concurrent clinically significant major disease that, in the opinion of the investigator, would make the subject unsuitable for enrollment 4. Participation within the past 30 days in a clinical study involving investigational drugs 5. Planned major surgery within 30 days prior to screening or during the study period
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Elastic properties of a forming clot using thromboelastograph to determine best bypassing agent | 6 months | This study will assess the feasibility of TEG-guided individualization of bypassing agent treatment of bleeding for severe hemophilia A patients with inhibitors. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Thrombin generation assay measuring the formation of thrombin during clot formation | 6 months | Thrombin generation assays will be performed to provide additional evidence supporting the TEG-guided individualization of bypassing agent treatment. |
| Number of participants with treatment-related adverse events | 1 year | The study will monitor short-term safety of patients whose bypassing agent treatment has been modified. |
Outcome results
None listed